- A Phase II trial of Intercept Pharmaceuticals' (ICPT) obeticholic acid (OCA) for the treatment of a chronic liver disease called nonalcoholic steatohepatitis (NASH) has been stopped early due to the therapy meeting the primary endpoint of the trial.
- NASH is caused by excessive fat accumulation in the liver, and can lead to cirrhosis, eventual liver failure and death. No drugs have been approved for the treatment of NASH.
- "On its current trajectory, the disease is projected to become the leading indication for liver transplant," Intercept says.
- Shares skyrocket 109%. (PR)
at Nasdaq.com (Jan 13, 2015)